Answers are grounded in this paper and cite their sources.
Background In the pediatric population, carbapenem-resistant Acinetobacter baumannii (CRAB) is a significant cause of hospital-acquired infections, particularly hospital-acquired urinary tract infections (HA-UTIs). There are a few studies on the molecular mechanisms of resistance to CRAB among children. Objective To detect the prevalence of CRAB among children with HA-UTIs and to evaluate associated carbapenemase genes and clinical risk factors. Methods This cross-sectional study included 100 children with HA-UTIs. Isolates were identified using standard microbiology techniques, and antimicrobial resistance (AMR) was detected according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Carbapenemase genes (blaOXA-23-like, blaOXA-24/40-like, blaOXA-58-like, and blaNDM) were detected by PCR. Data were statistically analyzed to assess the association between clinical factors and carbapenem resistance (CR). Results CR was identified in 73% of isolates. High rates of AMR were observed for cephalosporins and fluoroquinolones. The most prevalent gene was the blaOXA-23-like gene (60%), followed by the blaOXA-58-like (34%), the blaOXA-24/40-like (30%), and the blaNDM (15%). A significant association was observed between resistance to carbapenems and the carbapenemase genes blaOXA-23-like and blaNDM ( p < 0.05). Clinical factors like ICU admission and catheterization did not show a significant association with resistance. Conclusion Carbapenem resistance among pediatric Acinetobacter baumannii UTIs is highly prevalent and primarily driven by molecular mechanisms, particularly OXA-23 and NDM carbapenemases. This underscores the significance of molecular diagnostics and infection control in pediatric healthcare settings.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: